Cannamore Biotechs

About

Q&A

What is Cannamore Biotechs' primary focus?

Cannamore Biotechs is a preclinical- and clinical-stage research platform company focused on developing novel and improved cannabis-based treatment options. The company is specifically developing a CBD-based solution for bronchiolitis obliterans, peripheral neuropathy, and inflammatory bowel diseases.

When was Cannamore Biotechs founded?

Cannamore Biotechs was founded in October 2018.

Where is Cannamore Biotechs headquartered?

Cannamore Biotechs is headquartered in Bnei Brak, Center District, Israel.

What is the current employee count for Cannamore Biotechs?

Cannamore Biotechs has 1-10 employees.

Who is the CEO of Cannamore Biotechs?

David Bassa is the CEO and a founder of Cannamore Biotechs.

What is Cannamore Biotechs' current funding stage?

Cannamore Biotechs is currently in the Pre-Funding stage.

Which sector does Cannamore Biotechs primarily operate in?

Cannamore Biotechs primarily operates in the Health Tech & Life Sciences sector, with additional focus on Pharma & Medical Biotechnology and Medical Cannabis.

What is the product stage of Cannamore Biotechs' solutions?

Cannamore Biotechs' products are in the clinical trial stage.

Team · 1

David Bassa

Founder · CEO

LinkedIn ↗

Sectors & technology

Tags